Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that combining fexofenadine or ebastine with topical therapy significantly improved hair regrowth and reduced the severity of alopecia areata over 12 weeks compared to topical treatment alone.

This study reported that extended-release valproate significantly reduced seizure frequency and improved quality of life in epilepsy patients over six months, despite some adverse effects like weight gain and tremor.

In the phase 3 CAPItello-291 trial, capivasertib combined with fulvestrant significantly increased progression-free survival in patients with advanced breast cancer with specific genetic alterations, but the authors highlight that managing side effects like diarrhea, rash, and hyperglycemia is crucial for optimizing treatment adherence and outcomes.

The researchers presented a case study on Exo.Reset®, a cosmetic formulation using extracellular vesicle technology, demonstrating systematic application of recognized standards to ensure scientific rigor and regulatory compliance in skin rejuvenation product development, providing a practical model for EV-based cosmetic innovations.

The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.

This study found that the TYK2 inhibitor deucravacitinib did not significantly improve hair regrowth in patients with alopecia areata compared to placebo, suggesting it may not be effective for this condition. No new safety issues were identified.

In this study, women with telogen effluvium showed significant improvement in hair loss and hair growth density when treated with a combination of oral Pantovigar, a Microxidil-containing topical lotion, and mesotherapy with a placental preparation compared to those not receiving Pantovigar.

Topical tretinoin 0.025% cream is an effective treatment for Eruptive Vellus Hair Cysts in children.

In this study, researchers found that female rats exhibited more pronounced panic-related escape behavior during hypoxia, particularly in the diestrus phase, and that low-dose fluoxetine reduced this behavior, suggesting its potential for managing panic disorder symptoms related to hormonal cycles in women.

Higher doses of glucocorticoids increase the risk of blood clots in asthma patients.

This study identified numerous drugs with potential to trigger vitiligo, cautioning that these pharmacovigilance findings need further validation and that patients on these medications should be monitored for vitiligo development.

This report highlights a case where a woman's use of the dopamine agonist pramipexole for Parkinson's disease was associated with hair loss, which improved after discontinuing the drug.

This reference compilation details potential adverse skin reactions and other side effects associated with the antihypertensive drug Quinazil, including rare cases of skin angioedema and other dermatological reactions.

This study suggests that PF-0998425 is an effective androgen receptor antagonist for sebum control and androgenetic alopecia with rapid metabolism reducing the risk of systemic side effects.

Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.

This observational study found that while 96.6% of patients using valproic acid showed the expected clinical response, over half experienced adverse reactions like weight gain, hair loss, and hepatotoxicity, highlighting the need for personalized treatment approaches to minimize these side effects.

This case study indicates that older patients with NMOSD may show favorable clinical improvements with aggressive treatment, even when the intervention is initiated later in the disease course.

This review discusses fixed drug eruption (FDE) potentially linked to finasteride and emphasizes dermatologists' need to recognize its possible occurrence due to the drug's widespread use, but reports no new clinical results.

This study developed and tested Bicalutamide-loaded lipid vesicles in dissolving microarray patches for topical application, finding that they effectively deliver Bicalutamide through murine skin while maintaining a favorable safety profile, suggesting potential to improve treatments for androgenetic alopecia.

This study reported a 74% overall response rate for a new combination chemotherapy of mitoxantrone, etoposide, and prednisolone in patients with relapsed or refractory Hodgkin's disease or non-Hodgkin's lymphoma.

This case report describes a 31-year-old male who developed eosinophilic pleuropericardial effusion potentially linked to long-term valproic acid use, which resolved after adjusting his medication.

This study found that combining cyproterone acetate with topical eflornithine was a safe and effective treatment for facial hirsutism in women.

This study developed and validated a sensitive and rapid method to simultaneously measure alfuzosin and dutasteride in human plasma, enabling high-throughput analysis for pharmacokinetic and bioequivalence studies.

This study developed a validated HPLC method for accurately estimating dutasteride and its related compounds in capsules, suitable for routine and stability sample analysis.

This study found that a single 2 ml injection of TEEV every 4 weeks offers similar beneficial effects with fewer side effects compared to injecting the same dose every 2 weeks in postmenopausal women.

This study found that Adiantum capillus-veneris extract exhibited significant antidepressant and anti-anxiety effects in rats, likely due to its antioxidant and anti-inflammatory properties.

In this study, behavioral disturbances were commonly observed with levetiracetam, while somnolence was frequently reported with oxcarbazepine among patients with refractory epilepsy.